Organovo Holdings annonce des résultats prometteurs pour son médicament expérimental contre la stéatohépatite

((Automated translation by Reuters, please refer to the disclaimer

(Adding actions to paragraph 1, details throughout the article)

Organovo Holdings

ONVO.O

announced
Monday that its experimental drug for treating a type of
fatty liver disease has met the primary endpoint of a mid-stage study, causing its shares to soar by nearly 27%
in pre-market trading.

The non-steroidal drug, FXR314, significantly helped reduce
liver fat in patients with metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic steatohepatitis.

FXR314 also proved to be safe and well tolerated, according to
Organovo.

The company plans to present detailed study results at an upcoming conference.